Ranibizumab vs. pegaptanib: a cost-effectiveness study?
Wiwanitkit
Viroj
V
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000191:economics*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage / Q000191:economics*; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000191:economics* / Q000503:physiopathology; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D017048:Health Care Costs; D006302:Health Services Research; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy / Q000191:economics* / Q000503:physiopathology; D019057:Quality-Adjusted Life Years; D000069579:Ranibizumab; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000069579:Ranibizumab